Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amphotericin B + isavuconazole
- Development stage
- Preclinical
- Lead developer
- Basilea Pharmaceutica
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination antifungal therapy consisting of amphotericin B (a polyene antifungal) and isavuconazole (a triazole antifungal). This combination has demonstrated synergistic effects against various fungal pathogens, particularly Mucorales species that cause mucormycosis. In experimental models, the combination showed superior efficacy compared to either drug alone, with higher survival rates and greater reduction in fungal burden. The combination may be particularly valuable for treating severe, disseminated, or refractory fungal infections.
02
Targets
Beyond the preview
Go deeper on amphotericin B + isavuconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amphotericin B + isavuconazole.